Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P2GB
|
|||
| Former ID |
DNC012612
|
|||
| Drug Name |
MR-1526
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H25NO3
|
|||
| Canonical SMILES |
CC1C2CC3=C(C1(CCN2CC4CCC(=O)O4)C)C=C(C=C3)O
|
|||
| InChI |
1S/C19H25NO3/c1-12-17-9-13-3-4-14(21)10-16(13)19(12,2)7-8-20(17)11-15-5-6-18(22)23-15/h3-4,10,12,15,17,21H,5-9,11H2,1-2H3/t12-,15+,17+,19-/m0/s1
|
|||
| InChIKey |
HHASRPPPJAXSNL-IQRRUJBNSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor kappa (OPRK1) | Target Info | Inhibitor | [1] |
| Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Opioid prodynorphin pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| TCR Signaling Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.